The global cell therapy manufacturing market size is calculated at USD 5.55 billion in 2025 and is forecasted to reach around USD 18.89b illion by 2034, accelerating at a CAGR of 14.61% from 2025 to 2034. The North America cell therapy manufacturing market size surpassed USD 2.13 billion in 2024 and is expanding at a CAGR of 14.65% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell Therapy Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell Therapy Manufacturing Market, by Therapy Type
8.1.1. Allogenic Cell Therapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Autologous Cell Therapy
8.1.2.1. Market Revenue and Forecast
9.1. Cell Therapy Manufacturing Market, by Technology Type
9.1.1. Somatic Cell Technology
9.1.1.1. Market Revenue and Forecast
9.1.2. Cell Immortalization Technology
9.1.2.1. Market Revenue and Forecast
9.1.3. Viral Vector Technology
9.1.3.1. Market Revenue and Forecast
9.1.4. Genome Editing Technology
9.1.4.1. Market Revenue and Forecast
9.1.5. Cell Plasticity Technology
9.1.5.1. Market Revenue and Forecast
9.1.6. 3D Technology
9.1.6.1. Market Revenue and Forecast
10.1. Cell Therapy Manufacturing Market, by Source
10.1.1. IPSC (Induced Pluripotent Stem Cell)
10.1.1.1. Market Revenue and Forecast
10.1.2. Bone Marrow
10.1.2.1. Market Revenue and Forecast
10.1.3. Umbilical Cord
10.1.3.1. Market Revenue and Forecast
10.1.4. Adipose Tissues
10.1.4.1. Market Revenue and Forecast
10.1.5. Neural Stem
10.1.5.1. Market Revenue and Forecast
11.1. Cell Therapy Manufacturing Market, by Application
11.1.1. Musculoskeletal
11.1.1.1. Market Revenue and Forecast
11.1.2. Cardiovascular
11.1.2.1. Market Revenue and Forecast
11.1.3. Gastrointestinal
11.1.3.1. Market Revenue and Forecast
11.1.4. Neurological
11.1.4.1. Market Revenue and Forecast
11.1.5. Oncology
11.1.5.1. Market Revenue and Forecast
11.1.6. Dermatology
11.1.6.1. Market Revenue and Forecast
11.1.7. Others
11.1.7.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapy Type
12.1.2. Market Revenue and Forecast, by Technology Type
12.1.3. Market Revenue and Forecast, by Source
12.1.4. Market Revenue and Forecast, by Application
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapy Type
12.1.5.2. Market Revenue and Forecast, by Technology Type
12.1.5.3. Market Revenue and Forecast, by Source
12.1.5.4. Market Revenue and Forecast, by Application
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapy Type
12.1.6.2. Market Revenue and Forecast, by Technology Type
12.1.6.3. Market Revenue and Forecast, by Source
12.1.6.4. Market Revenue and Forecast, by Application
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapy Type
12.2.2. Market Revenue and Forecast, by Technology Type
12.2.3. Market Revenue and Forecast, by Source
12.2.4. Market Revenue and Forecast, by Application
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapy Type
12.2.5.2. Market Revenue and Forecast, by Technology Type
12.2.5.3. Market Revenue and Forecast, by Source
12.2.5.4. Market Revenue and Forecast, by Application
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapy Type
12.2.6.2. Market Revenue and Forecast, by Technology Type
12.2.6.3. Market Revenue and Forecast, by Source
12.2.6.4. Market Revenue and Forecast, by Application
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapy Type
12.2.7.2. Market Revenue and Forecast, by Technology Type
12.2.7.3. Market Revenue and Forecast, by Source
12.2.7.4. Market Revenue and Forecast, by Application
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapy Type
12.2.8.2. Market Revenue and Forecast, by Technology Type
12.2.8.3. Market Revenue and Forecast, by Source
12.2.8.4. Market Revenue and Forecast, by Application
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapy Type
12.3.2. Market Revenue and Forecast, by Technology Type
12.3.3. Market Revenue and Forecast, by Source
12.3.4. Market Revenue and Forecast, by Application
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapy Type
12.3.5.2. Market Revenue and Forecast, by Technology Type
12.3.5.3. Market Revenue and Forecast, by Source
12.3.5.4. Market Revenue and Forecast, by Application
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapy Type
12.3.6.2. Market Revenue and Forecast, by Technology Type
12.3.6.3. Market Revenue and Forecast, by Source
12.3.6.4. Market Revenue and Forecast, by Application
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapy Type
12.3.7.2. Market Revenue and Forecast, by Technology Type
12.3.7.3. Market Revenue and Forecast, by Source
12.3.7.4. Market Revenue and Forecast, by Application
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapy Type
12.3.8.2. Market Revenue and Forecast, by Technology Type
12.3.8.3. Market Revenue and Forecast, by Source
12.3.8.4. Market Revenue and Forecast, by Application
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapy Type
12.4.2. Market Revenue and Forecast, by Technology Type
12.4.3. Market Revenue and Forecast, by Source
12.4.4. Market Revenue and Forecast, by Application
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapy Type
12.4.5.2. Market Revenue and Forecast, by Technology Type
12.4.5.3. Market Revenue and Forecast, by Source
12.4.5.4. Market Revenue and Forecast, by Application
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapy Type
12.4.6.2. Market Revenue and Forecast, by Technology Type
12.4.6.3. Market Revenue and Forecast, by Source
12.4.6.4. Market Revenue and Forecast, by Application
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapy Type
12.4.7.2. Market Revenue and Forecast, by Technology Type
12.4.7.3. Market Revenue and Forecast, by Source
12.4.7.4. Market Revenue and Forecast, by Application
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapy Type
12.4.8.2. Market Revenue and Forecast, by Technology Type
12.4.8.3. Market Revenue and Forecast, by Source
12.4.8.4. Market Revenue and Forecast, by Application
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapy Type
12.5.2. Market Revenue and Forecast, by Technology Type
12.5.3. Market Revenue and Forecast, by Source
12.5.4. Market Revenue and Forecast, by Application
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapy Type
12.5.5.2. Market Revenue and Forecast, by Technology Type
12.5.5.3. Market Revenue and Forecast, by Source
12.5.5.4. Market Revenue and Forecast, by Application
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapy Type
12.5.6.2. Market Revenue and Forecast, by Technology Type
12.5.6.3. Market Revenue and Forecast, by Source
12.5.6.4. Market Revenue and Forecast, by Application
13.1. Abbott
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Thermo Fisher Scientific
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Catalent, Inc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Bio-Techne
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Cytiva
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Lonza
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. The Discovery Labs
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Novartis AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Bristol-Myers Squibb Company
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Gilead Sciences, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample